These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1010 related items for PubMed ID: 16379016

  • 41. Heart failure: is there a role for angiotensin II receptor blockers?
    Boucher M, Ma J.
    Issues Emerg Health Technol; 2002 Sep; (38):1-4. PubMed ID: 12243202
    [Abstract] [Full Text] [Related]

  • 42. Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure--a population study.
    Hudson M, Rahme E, Behlouli H, Sheppard R, Pilote L.
    Eur J Heart Fail; 2007 Sep; 9(6-7):602-9. PubMed ID: 17383932
    [Abstract] [Full Text] [Related]

  • 43. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure: an observational study of treatment rates and clinical outcome.
    Gotsman I, Rubonivich S, Azaz-Livshits T.
    Isr Med Assoc J; 2008 Mar; 10(3):214-8. PubMed ID: 18494235
    [Abstract] [Full Text] [Related]

  • 44. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction.
    Masoudi FA, Rathore SS, Wang Y, Havranek EP, Curtis JP, Foody JM, Krumholz HM.
    Circulation; 2004 Aug 10; 110(6):724-31. PubMed ID: 15289383
    [Abstract] [Full Text] [Related]

  • 45. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker).
    Dimopoulos K, Salukhe TV, Coats AJ, Mayet J, Piepoli M, Francis DP.
    Int J Cardiol; 2004 Feb 10; 93(2-3):105-11. PubMed ID: 14975535
    [Abstract] [Full Text] [Related]

  • 46. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation.
    Richter B, Derntl M, Marx M, Lercher P, Gössinger HD.
    Am Heart J; 2007 Jan 10; 153(1):113-9. PubMed ID: 17174648
    [Abstract] [Full Text] [Related]

  • 47. Valsartan in chronic heart failure.
    Ripley TL.
    Ann Pharmacother; 2005 Mar 10; 39(3):460-9. PubMed ID: 15687480
    [Abstract] [Full Text] [Related]

  • 48. [The role of ACE inhibitors and angiotensin receptor blockers in the treatment and prevention of chronic heart failure].
    Kárpáti P.
    Orv Hetil; 2005 May 01; 146(18):827-31. PubMed ID: 15926627
    [Abstract] [Full Text] [Related]

  • 49. [When after myocardial infarction a pump weakness remains. ACE inhibitors and AT-1 blockers equivalent].
    MMW Fortschr Med; 2003 Dec 04; 145(49):18-9. PubMed ID: 14963986
    [No Abstract] [Full Text] [Related]

  • 50. Angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, or both in chronic heart failure.
    Young JB.
    Heart Fail Clin; 2005 Apr 04; 1(1):39-47. PubMed ID: 17386832
    [No Abstract] [Full Text] [Related]

  • 51. Angiotensin receptor antagonists and ACE inhibitors.
    Howes LG, Christie N.
    Aust Fam Physician; 1998 Oct 04; 27(10):914-7, 919-21. PubMed ID: 9798290
    [Abstract] [Full Text] [Related]

  • 52. [Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
    Kubota T, Takeshita A.
    Nihon Rinsho; 2003 May 04; 61(5):801-6. PubMed ID: 12755006
    [Abstract] [Full Text] [Related]

  • 53. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG.
    J Indian Med Assoc; 2009 Mar 04; 107(3):178-82. PubMed ID: 19810392
    [Abstract] [Full Text] [Related]

  • 54. Angiotensin-converting enzyme inhibitor and/or angiotensin receptor antagonist for the postmyocardial infarction patient.
    Scott RL.
    Cardiol Clin; 2008 Feb 04; 26(1):73-7, vii. PubMed ID: 18312907
    [Abstract] [Full Text] [Related]

  • 55. [Blockade of the renin-angiotensin system. ACE inhibitors, angiotensin II antagonists or both?].
    Karlsen FM, Kamper AL.
    Ugeskr Laeger; 2003 Oct 13; 165(42):4006-9. PubMed ID: 14610833
    [No Abstract] [Full Text] [Related]

  • 56. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P.
    J Hypertens; 2008 Jul 13; 26(7):1282-9. PubMed ID: 18550998
    [Abstract] [Full Text] [Related]

  • 57. Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling.
    Healey JS, Morillo CA, Connolly SJ.
    Curr Opin Cardiol; 2005 Jan 13; 20(1):31-7. PubMed ID: 15596957
    [Abstract] [Full Text] [Related]

  • 58. Effects of angiotensin converting enzyme inhibitors on remodeling in clinical trials.
    Greenberg BH.
    J Card Fail; 2002 Dec 13; 8(6 Suppl):S486-90. PubMed ID: 12555162
    [Abstract] [Full Text] [Related]

  • 59. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
    Volpe M, Tocci G, Sciarretta S, Verdecchia P, Trimarco B, Mancia G.
    J Hypertens; 2009 May 13; 27(5):941-6. PubMed ID: 19381108
    [Abstract] [Full Text] [Related]

  • 60. Role of angiotensin receptor blockers in the prevention and treatment of arrhythmias.
    Garg S, Narula J, Marelli C, Cesario D.
    Am J Cardiol; 2006 Mar 15; 97(6):921-5. PubMed ID: 16516603
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 51.